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ABSTRAK 
Objektif. Analisa secara kualitatif menggunakan skan tulang sering kali di rumitkan 
dengan kewujudan penyakit degeneratif sendi tulang belakang lebih-lebih lagi pada 
pesakit yang sudah berusia. Tujuan utama kajian ini adalah untuk membandingkan secara 
semi-kuantitatif akumulasi pengesan 99mTc-MDP di antara penyakit degeneratif sendi dan 
metastatik kanser pada tulang belakang menggunakan SPECT SUV. 
Subjek dan Kaedah. Skan tulang dengan SPECT/CT menggunakan 99mTc-MDP telah di 
lakukan pada 34 pesakit kanser prostat. SPECT/CT di lakukan berdasarkan garis panduan 
institusi kami. Pengiraan standardized uptake value maximum (SUVmax) berdasarkan 
berat badan pada 238 vertebra normal yang di lihat pada SPECT/CT telah di lakukan 
sebagai asas. Sebanyak 211 lesi telah di kenal pasti pada skan tulang. Morfologi lesi telah 
dicirikan berdasarkan pemerhatian gambar pada CT skan dos rendah. Analisa secara 
semi-kuantitatif telah di buat menggunakan SUVmax terhadap 89 lesi untuk penyakit 
degeneratif sendi dan 122 untuk metastatik.  
Keputusan. Mean SUVmax untuk vertebra normal adalah 7.08 ± 1.97, 12.59 ± 9.01 
untuk penyakit degeneratif sendi dan 36.64 ± 24.84 untuk metastatik kanser pada tulang 
belakang. SUVmax untuk metastatik kanser pada tulang belakang adalah lebih tinggi 
daripada penyakit degeneratif sendi dengan ketara (nilai p <0.05). Untuk menganalisa 
ketepatan diagnosis, kurva ciri operasi penerima (ROC) telah dibuat dan didapati 
kawasan di bawah lengkung (AUC) adalah agak tinggi pada 0.874 (95% CI: 0.826-
0.921). Nilai SUVmax   ≥ 20 dapat membezakan antara metastatik kanser pada tulang 
belakang daripada penyakit degeneratif sendi dengan sensitiviti sebanyak 73.8% dan 
spesifisiti 85.4%. 
 xiii 
Kesimpulan. SPECT SUVmax pada metastatik kanser pada tulang belakang adalah lebih 
tingggi secara ketara daripada penyakit degeneratif sendi. Analisa secara semi-kuantitatif 
menggunakan SUVmax boleh menjadi pelengkap pada analisa secara kualitatif. Nilai 
SUVmax  ≥ 20 boleh di gunakan untuk membezakan antara metastatik kanser tulang 
belakang dan penyakit degeneratif sendi. Namun begitu, nilai tersebut tidak sesuai di 
gunakan secara klinikal kerana terdapat pertindihan yang besar antara nilai SUVmax pada 
penyakit degeneratif sendi dan metastatik kanser tulang belakang. 
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ABSTRACT 
Objective. Qualitative interpretation in bone scan is often complicated by the presence 
of degenerative joint disease (DJD) especially in the elderly patient. The aim of this study 
is to compare objectively 99mTc-MDP tracer uptake between DJD and osseous metastases 
of the spine using semi-quantitative assessment with SPECT SUV. 
Subjects and Methods. Bone scan with SPECT/CT using 99mTc-MDP were performed 
in 34 patients diagnosed with prostate carcinoma. SPECT/CT were performed based on 
our institutional standard guidelines. SUVmax based on body weight in 238 normal 
vertebrae visualized on SPECT/CT were quantified as baseline. A total of 211 lesions in 
the spine were identified on bone scan. Lesions were characterized into DJD or bone 
metastases based on its morphology on low dose CT. Semi-quantitative evaluation using 
SUVmax were then performed on 89 DJD and 122 metastatic bone lesions. 
Results. The mean SUVmax for normal vertebrae was 7.08 ± 1.97, 12.59 ± 9.01 for DJD 
and 36.64 ± 24.84 for bone metastases. The SUVmax of bone metastases were 
significantly greater than DJD (p value <0.05). To assess for diagnostic accuracy, receiver 
operating characteristic (ROC) curve was performed. The area under the curve (AUC) 
was found to be fairly high at 0.874 (95% CI: 0.826-0.921). The cut-off SUVmax value ≥ 20 gave a sensitivity of 73.8% and specificity of 85.4% in differentiating bone 
metastases from DJD. 
Conclusion. SPECT SUVmax was significantly higher in bone metastases than DJD. 
Semi-quantitative assessment with SUVmax can complement qualitative analysis. A cut-
off SUVmax of ≥ 20 can be used to differentiate bone metastases from DJD.   However, 
it is not feasible to be applied clinically due to the considerable overlap of SUVmax 
between DJD and bone metastases.
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1.0 INTRODUCTION 
 
 Early diagnosis of bone metastasis is essential in prostate cancer to aid the 
referring physician in choosing the appropriate therapy, assessing the extent of bony 
involvement, monitoring of treatment response and assessing for possible complications 
(McLoughlin et al., 2016). In general, bone is the 3rd most common site of cancer 
metastasis after lung and liver (Macedo et al., 2017). In prostate cancer, bone metastases 
are seen in up to 65-75% of patients and commonly involved the axial skeleton, the site 
of active bone marrow (Langsteger et al., 2016 ; Macedo et al., 2017 ; O’Sullivan, 2015). 
It also represents the initial and main site of metastases in approximately 80% of cases 
(Tombal, 2012).  
 Whole body bone scan (WBBS) is widely used for the assessment of bone 
metastasis in prostate cancer owing to its high sensitivity, availability and affordability 
(Macedo et al., 2017). Often it is used for staging in the early stage of prostate cancer in 
order to decide on the appropriate treatment or making decision on change of therapy in 
patient with advanced disease (Donohoe et al., 2017). In spite of its high sensitivity, 
planar WBBS has low specificity due to the accumulation of the radiotracer in traumatic, 
degenerative and inflammatory lesions which may cause false positive findings 
(Langsteger et al., 2016). In addition, increased in tracer uptake in degenerative joint 
disease of the spine is also common in men more than 50 years old (Muzahir et al., 2015 
; O’Sullivan, 2015).  
 
 
 3 
Single photon emission computed tomography (SPECT) which shows axial slices 
of radiopharmaceutical uptake (O’Sullivan, 2015), performed in limited regions of the 
body is used to clarify indeterminate lesions by identifying certain patterns of radiotracer 
accumulation that is more indicative of either benign or malignant disease (Helyar et al., 
2010 ; Love et al., 2003). Compared to planar bone scan, SPECT of the spine has shown 
to detect 20 to 50% more lesions (Sapir, 2005) and has higher sensitivity and specificity 
(Love et al., 2003). 
 The introduction of hybrid single photon emission computed tomography/ 
computed tomography (SPECT/CT) has further enhanced the sensitivity and specificity 
of bone scan (Kuwert, 2014). SPECT/CT enables anatomical correlation, characterizing 
morphologic changes and attenuation correction of radiotracer uptake on CT which led 
to significant increase in diagnostic accuracy especially in assessing indeterminate lesions 
on planar WBBS (McLoughlin et al., 2016). SPECT/CT has been shown to define more 
than 90% indeterminate lesions on bone scan (Römer et al., 2006).  
 In clinical practice, disease progression or regression in bone metastases is 
commonly characterized by increase or decrease in number of bone lesions. Qualitative 
interpretation of bone scan with SPECT and SPECT/CT is subjective and interpreter 
dependent (Beck et al., 2016). This poses difficulty in differentiating between malignant 
and degenerative changes both of which will give rise to increased tracer uptake on bone 
scan. There is no defined, standardized value or cut-off point to differentiate between 
degenerative joint disease and bone metastases objectively. An objective semi-
quantitative analysis was proposed in a similar manner to positron emission (PET) 
standardized uptake value (SUV) as this could be useful in determining treatment 
response.  
 4 
 To date, there is little data available on the usage of semi-quantitative 
measurement with SPECT SUV in differentiating degenerative joint disease (DJD) from 
metastatic bone disease. Furthermore, the clinical utility of SUV in SPECT based 
radiotracers are not well established and not widely used in clinical practice. The aim of 
this study is to evaluate the utility of semi-quantitative assessment with SPECT SUV in 
differentiating DJD from bone metastasis of the spine in prostate cancer patients who 
underwent bone scan in Hospital Universiti Sains Malaysia (HUSM).  
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2.0 LITERATURE REVIEW 
 
2.1 NORMAL ANATOMY OF PROSTATE 
 
 The prostate is a small gland which is a part of the male reproductive system. It 
has the shape and size of a walnut. It weighs from 7 to 16g with a mean of 11g in adult 
and surrounds the urethra at the neck of urinary bladder (Kumar, 1995). It is located 
anterior to the rectum and in between the urogenital diaphragm and bladder. The urethra 
runs through the prostate gland centrally from the urinary bladder to the penis, allowing 
urine and semen excretion from the body.  
 
Figure 2.1: Anatomy of prostate  
(adapted from 
https://www.hopkinsmedicine.org/healthlibrary/conditions/prostate_health/anatomy_of_
the_prostate_gland_85,P01257 accessed on 13th February 2019) 
 
 The function of prostate gland includes the control of urine excretion from the 
bladder, seminal fluid transmission, reduction of urethral activity via secretion of 
prostatic fluids and also aids in testosterone metabolism. The main male hormone 
testosterone is being produced by the testes. Histologically, the prostate gland can be 
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divided into lobes (two laterals, anterior, posterior and median) and three zones, namely 
the peripheral, transitional and central zone (Kumar, 1995).  
 
2.2 EPIDEMIOLOGY 
 
 Prostate cancer is the 2nd most frequent malignancy in male and the 4th most 
common cancer for both male and female worldwide. In 2012, an estimate of 1.1 million 
prostate cancer cases were diagnosed which accounts for 15% of cancer diagnosed in 
men. The incidence however varied across the region worldwide with 70% of cases 
occurring in more developed countries (Ferlay et al., 2015). High incidence of prostate 
cancer can be found in North America and Australia/ New Zealand while the lowest 
incidence is seen in the Asian population (Ferlay et al., 2015 ; Zhou et al., 2016 ; Gjertson, 
2011). This is primarily attributed to the prevalence of PSA testing which was followed 
by biopsy of the prostate gland in the developed regions especially in men aged 50 years 
or older (Zhou et al., 2016 ; Tombal, 2012). In terms of mortality, prostate cancer 
represents 6.6% (or 307,000 deaths) of the total cancer mortality in male and is the 5th 
highest cause of death from cancer in men. The mortality rate is however high in the 
African population, intermediate in Oceania and Americas and low in Asian population 
(Ferlay et al., 2015). 
 Based on the Malaysian National Cancer Registry 2007-2011 (Manan et al., 2007-
2011), prostate cancer is the 5th most frequent malignancy in Malaysian men and ranked 
11th overall in Malaysia. Cancer of the prostate accounts for 6.7% of all cancers in the 
Malaysian male population with a lifetime risk of 1 in 117. The incidence of prostate 
cancer is at 6.7 per 100,000 and increased with advanced age. The highest incidence of 
 8 
prostate cancer is seen in Penang (at 13.8 per 100,000) while the lowest incidence is seen 
in Wilayah Persekutuan Labuan (at 2.8 per 100,000). The state of Kelantan however has 
an incidence of 5.9 per 100,000. In Malaysia, prostate cancer is most common in the 
Chinese, followed by the Indian and Malay race. It is often diagnosed late as 41.6% of 
prostate cancer patients presents to the tertiary center with stage IV disease.  
 
Figure 2.2 Incidence of prostate cancer per 100,000 males according to states in 
Malaysia. Adapted from (Manan et al., 2007-2011) 
 
 
 
Figure 2.3 Incidence of prostate cancer per 100,000 males in Malaysia based on age 
group. Adapted from (Manan et al., 2007-2011) 
 
 
 9 
2.3 SYMPTOMS & DIAGNOSIS OF PROSTATE CANCER 
 
 Prostate cancer is often multifocal and commonly found in the peripheral zone 
(80 to 85%) followed by transitional zone (10-15%) and central zone (5 to 10%). 
Adenocarcinoma is the most common histology which represents more than 95% of 
prostate cancer. Growth of prostate cancer follows a multistep process starting from 
prostate intraepithelial neoplasia, which is a precursor for carcinoma. Initially, the 
prostate cancer cells are confined to the normal gland. Further cell mutation leads to 
disease progression and metastasis. Prostate cancer cells are sensitive to androgen 
receptor activation and with progression of disease, there is upregulation and mutation of 
the androgen receptors (Strauss et al., 2017). 
 Prostate cancer is generally slow growing, and patient is often asymptomatic for 
a number of years. The disease often affect urination owing to its vicinity to the urethra. 
Symptoms of prostate cancer includes an increased in urinary frequency, nocturia, 
hematuria, poor stream and dysuria. Sexual function can also be affected, manifested by 
painful ejaculation or difficulty in attaining erection. Clinically, abnormalities of the 
prostate can be assessed by digital rectal examination (DRE). The prostate can be felt as 
hard and craggy in the presence of cancer. Often however, prostate may feel normal in 
spite of the presence of cancer cells. It is recommended that men aged more than 50 years 
have yearly DRE and prostate specific antigen (PSA) test (Zhou et al., 2016). DRE is 
used to determine whether patient need further investigation.  
 The serum PSA is a glycoprotein synthesized by the prostate epithelial cells. Its 
function is to dissolve seminal clot post ejaculation which facilitates the transport of 
sperm along the female reproductive tract. The concentration of PSA is found to be high 
in seminal fluid with a range of 0.5 to 2.0 mg/mL, but is much lower in blood. Its elevation 
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in the blood in disease states have been postulated to be caused by the disruption of 
prostate gland cellular architecture (Gretzer, 2002). Elevation of PSA may indicate 
prostate cancer. However, serum PSA is not a specific prostate cancer marker as its rise 
can also be seen in prostatic trauma, inflammation and benign proliferation (Gretzer, 2002 
; Gjertson, 2011). The normal values of PSA for men over the  age of 40 is equal or less 
than 4.0 ng/mL (Gretzer, 2002). In prostate cancer, elevation of PSA cannot differentiate 
between low grade and high grade cancer (Gjertson, 2011). Nonetheless, higher PSA 
level signifies advanced disease (Donohoe et al., 2017).  
 Transrectal ultrasound is being used to measure the prostate size and density. 
Biopsy for histological confirmation is done with guidance from ultrasound where 10 to 
12 tissue samples or cores are being taken for histopathological confirmation. CT scan on 
the other hand can assess for cancer spread to regional lymph nodes. Magnetic resonance 
imaging (MRI) uses magnetic field which is a non-ionizing radiation that creates a clear 
picture of the prostate gland. It is also the imaging modality used to assess metastases in 
the bone marrow cavity before osteoblastic lesion manifest as a focal of uptake in skeletal 
scintigraphy (O’Sullivan, 2015). 
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2.4 STAGING AND RISK ASSESSMENT 
 
 The tumor-node-metastasis (TNM) system, developed by the American Joint 
Committee on Cancer (AJCC) is used for pre-therapy staging in prostate cancer. For the 
T (tumor) staging, it is based on DRE, cancer involvement in prostate on biopsy and 
radiological imaging such as CT scan and MRI. Nodal metastases are assessed based on 
anatomic enlargement of lymph nodes on CT scan or MRI. PET/CT tracers are however 
able to identify nodal metastases prior to enlargement of the lymph nodes. Metastases on 
the other hand is also evaluated by CT scan and MRI with the addition of bone 
scintigraphy as bone is the commonest site for distant metastasis in prostate cancer. 
 
Figure 2.4 AJCC TNM criteria for prostate cancer 7th edition (Adapted from 
https://cancerstaging.org/references-tools/quickreferences/Pages/default.aspx accessed 
on 25th September 2018). 
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 Histologic grading is essential in disease prognostication of clinically localized 
prostate cancer. Over the years, the Gleason score has been the widely accepted standard 
for prostate cancer grading where the cancers are scored based on its appearance under 
the microscope. The Gleason grading system practically assess the architectural pattern 
of the prostate cancer. It scores both the primary grade or dominant patterns (>50%) and 
non-dominant or secondary patterns (5 to 50%) of cancer from 1 to 5, where 1 is well 
differentiated and 5 is poorly differentiated. The Gleason score is the total score of the 
dominant and non-dominant pattern (Parker et al., 2015). 
 
 
Figure 2.5 Gleason’s Pattern Scale. (Adapted from 
https://www.prostateconditions.org/about-prostate-conditions/prostate-cancer/newly-
diagnosed/gleason-score accessed on 25th September 2018) 
 
 Localized disease with Gleason sum of 8, 9 or 10 can progress to metastasis which 
can lead to death in a short time span. Those with low grade cancer (Gleason sum of £6) 
however, may not demonstrate disease progression in spite of not having any treatment. 
In terms of mortality, patients with Gleason sum of 7 and 8 to 10 has a higher rate of 
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death. On the contrary, patient with Gleason score of £6 is at low risk of cancer related 
death (Gjertson, 2011).  
 
2.5 TREATMENT OF PROSTATE CANCER 
 
 The treatment of prostate cancer is risk adjusted and patient specific. Early stage 
prostate carcinoma is often treated with the aim of cure. Therapy includes active 
surveillance, radical prostatectomy, radiotherapy and seeds implant (Parker et al., 2015). 
Local therapy is indicated for localized low or intermediate risk disease while bone 
metastases patients are generally treated with systemic therapy (Tombal, 2012). 
 Hormonal therapy is commonly used in prostate cancer that has spread beyond 
the prostate gland and also in cases of cancer recurrence post radiotherapy or radical 
prostatectomy. Prostate cancer needs fuel to grow and survive which is mainly provided 
by the hormone testosterone. It is known that androgen deprivation therapy (ADT) by 
using drug or surgery, limit or slow the growth of prostate cancer by reducing the levels 
of androgen. Most of the prostate cancer cells will respond to ADT but some may become 
independent and thus resistant to hormonal therapy (Strauss et al., 2017). Chemotherapy 
with docetaxel is reserved for metastatic prostate cancer that is resistant to ADT (Strauss 
et al., 2017 ; Parker et al., 2015). A change in therapy is often considered based on 
symptoms, PSA elevation, presence of metastasis or progression of disease (Donohoe et 
al., 2017).  
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2.6 BONE METASTASES IN PROSTATE CANCER 
 
 Prostate cancer has a high tendency for bone metastases. The occurrence of 
skeletal metastases correlates with PSA level and Gleason scoring. The incidence of bone 
metastases is approximately 2% in patient with PSA of <10 ng/ml, while the likelihood 
of bone metastases is at 16% for PSA of >20 ng/ml. In terms of Gleason score, bone 
metastases are seen in 6% of patients with a score of <6 compared to 30% in patient with 
Gleason score of  >7 (Donohoe et al., 2017). 
 More than 90% of bone metastases are found in the axial skeleton, the site of 
active red marrow which can lead to skeletal complications. Skeletal metastases occur 
most commonly via hematogenous spread, mainly through the venous pathway. The 
tumor cells detached from its primary site and enters the blood circulation. It then 
survived the host immune response and vascular resistance (Maccauro et al., 2011 ; Sapir, 
2005). Entry of tumor cells to the well vascularized active bone marrow is facilitated by 
its sluggish and slow blood flow (O’Sullivan, 2015).  
 After bone colonization, tumor cells released cytokines and growth factors which 
disrupt normal bone turnover. Parathyroid-related hormone protein, tumor necrosis factor 
alpha and cytokines such as interleukin-1 upregulates the osteoclast by increasing the 
production of receptor activator of nuclear kappa B ligand (RANKL) causing osteolysis. 
On the other hand, insulin-like growth factors, epidermal growth factor and transforming 
growth factor alpha causes osteosclerosis from upregulation of osteoblasts (O’Sullivan, 
2015 ; Maccauro et al., 2011). In bone metastases, there is a disruption in the balance 
between osteoblast mediated bone formation and osteoclast mediated bony destruction 
(So et al., 2012 ; Maccauro et al., 2011) . 
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 In the marrow, as the tumor cells enlarge, the adjacent bone underwent 
osteoblastic and osteolytic changes. The radiographic appearance of bone metastases can 
be lytic, sclerotic or a mixture of both lytic-sclerotic lesion depending on the balance 
between osteolytic and osteoblastic processes. Aggressive bone metastases tend to be 
lytic while sclerosis signifies slower tumor growth (Sapir, 2005). In prostate cancer, there 
is a characteristic association between osteoblastic response to the presence of metastatic 
cancer cells. 
 
 
Figure 2.6 Mechanism of tumor metastases to the skeletal system in prostate cancer. 
(Adapted from https://academic.oup.com/edrv/article/19/1/18/2530783 accessed on 
25th September 2018) 
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2.7 MANAGEMENT OF BONE METASTASES IN PROSTATE CANCER 
 
 Bone metastases commonly caused skeletal related events (SRE), complications 
that are associated with significant morbidity (Cook et al., 2011). By definition, SRE 
encompassed pathological fracture, hypercalcemia, spinal cord compression and the 
necessity for patient to undergo radiotherapy or surgery to the bone (So et al., 2012 ; 
Coleman et al., 2014 ; Klaassen et al., 2017). Replacement of bone marrow hematopoietic 
cell by prostate cancer cells can also lead to anemia (Tombal, 2012). If left untreated, up 
to 50% of advanced prostate cancer patients will experienced SRE within 2 years (So et 
al., 2012) and it is associated with significant loss of mobility, reduction in quality of life 
and increased in cost of treatment (Coleman et al., 2014 ; Klaassen et al., 2017). Presence 
of 3 or more lesions on bone scan also increased the risk of SRE (So et al., 2012).  
 Treatment modalities include analgesics, bisphosphonates (like zoledronic acid), 
receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor and bone targeted 
radionuclide therapy such as Radium-223 (223Ra) (So et al., 2012). 223Ra has been shown 
to improve the survival of patients diagnosed with bone metastases and delays skeletal 
related event (Parker et al., 2015 ; Klaassen et al., 2017). In spite of the advancement of 
bone targeted therapies, bone metastases are still considered incurable (Tombal, 2012 ; 
Coleman et al., 2014). Mortality from prostate cancer is often due to complications from 
bone metastases (Klaassen et al., 2017). 
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2.8 IMAGING MODALITIES IN BONE METASTASES 
 
Plain radiographs are widely available and often used in the initial assessment of 
bone metastases. However, it has limited contrast between cortical and trabecular bone. 
Unlike plain radiographs, CT scan offers excellent resolution between cortical and 
trabecular bone and enables bone visualization in multiple planes resulting to an increased 
in sensitivity without the effect of superposition. However, both plain radiographs and 
CT scan requires 50 to 70% of bony destruction for lesion detection, reveals only 
structural bony alterations and unable to fully differentiate between sclerotic lesion from 
progression of disease from those caused by bone remodeling in treatment response 
(O’Sullivan, 2015 ; Heindel et al., 2014). 
MRI is the imaging of choice for assessment of bone metastases in the marrow 
cavity due its good resolution in soft tissue with a sensitivity and specificity of 95% and 
90% respectively. It has the added advantage of detecting intramedullary bone metastases 
prior to cortical bone destruction and before the manifestation of radiotracer uptake from 
osteoblastic process in a bone scan. However, MRI has poor visualization of bone with 
low marrow volume due to its short T2 relaxation time (O’Sullivan, 2015 ; Heindel et al., 
2014). 
Radionuclide bone scan either with SPECT [like 99mTc-methylene diphosphonate 
(MDP)] or PET [like 18F-sodium fluoride (NaF)] tracer is commonly used in nuclear 
medicine procedure in the assessment of skeletal metastasis. In comparison to SPECT, 
PET has superior spatial and image resolution. Uptake of radiotracer relies on blood flow, 
osteoblastic process and its extraction efficiency. The radiotracer concentrates at bone 
diphosphonates which is chemiabsorbed by the osseous matrix into the hydroxyapatite 
crystal on the surface of bone. The advantage of bone scan is from its ability to image the 
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whole skeleton, high sensitivity and early detection of skeletal metastasis with as little as 
5 to 10% of bone alteration exhibiting abnormal tracer accumulation. Its limitation lies in 
its low specificity, where non-metastatic lesions such as degenerative joint disease and 
fracture may display abnormal tracer accumulation, assess osteoblastosis rather than 
cancer proliferation and little or absent tracer uptake seen in osteolytic lesions 
(O’Sullivan, 2015 ; Heindel et al., 2014).  
Compared to 99mTc-MDP, 18F-NaF is superior with increased in sensitivity and 
specificity in detecting skeletal metastasis. However, 18F-NaF limited availability and 
cost restrict its usage. 18F-fluorodeoxyglucose (FDG) is a glucose analog where its uptake 
reflects tumor metabolism and is superior than both 99mTc-MDP and 18F-NaF in detecting 
lytic and purely bone marrow metastasis (Bastawrous et al., 2014). 
Technological advancement enables the usage of hybrid imaging such as 
SPECT/CT, PET/CT and PET/MRI which allows morphological correlation from 
functional imaging with the added advantage of quantitative assessment with SUV 
(O’Sullivan, 2015 ; Heindel et al., 2014).  
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2.9 MONITORING OF BONE METASTASES 
 
 Monitoring of treatment response in bone metastases is laborious. In practice, 
assessment is based on clinical examination, biochemical markers such as PSA and 
alkaline phosphatase (ALP) which is a serum marker for osteoblastic proliferation 
(Tombal, 2012) and imaging modalities. Nonetheless, these methods are not sensitive and 
non-specific (Cook et al., 2011). 
 Visually counting the number of lesions on bone scan has been a commonly used 
method to assess extent of bone metastases. Bone scan image interpretation based on 
changes of lesion intensity and size is subjected to inter-observer variation which will 
cause difficulty in comparing images in the long term (Zafeirakis, 2014). An objective 
quantitative tool is thus essential to monitor the progression of bone metastases.  
With the improvement of therapy of bone metastases, better methods are needed 
to characterize disease burden at the initial stage and to assess treatment response 
(Zafeirakis, 2014). In addition, radiographic changes in treatment response takes a couple 
of months to occur (Cook et al., 2011 ; O’Sullivan, 2015). MRI can be used to assess 
treatment response in skeletal metastases based on number and size of lesions. Further 
studies are however needed to ascertained T1 and diffusion weighted imaging (DWI) 
characteristics in the evaluation of therapy response (O’Sullivan, 2015). Comparing 
qualitative analysis with semi-quantitative analysis using SUV in bone scan have 
demonstrated almost perfect inter-observer agreement between interpreters compared to 
visual analysis alone (Beck et al., 2016). Lei Mao et al. (2015) has concluded that SUV 
SPECT can be used as an absolute quantitative parameters in the follow up of prostate 
cancer patients with bone metastases. Hence, quantification of tracer uptake ensures 
consistency in monitoring of treatment response. 
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2.10 STANDARDIZED UPTAKE VALUE (SUV) 
 
SUV is a commonly used semiquantitative parameter to calculate accumulation 
of tracer in PET studies especially in 18F-FDG PET/CT. Its clinical application lies in 
measuring the relative change in SUV to assess treatment response. The measured 
radiotracer within a region of interest (ROI) is normalized to the average accumulation 
of radiotracer in the body which is estimated by the radiopharmaceutical injected dose 
divided by the body size. The measurement of body size can be based on body surface 
area (bsa), lean body mass (lbm) and body weight (bw). However, SUV based on body 
weight is commonly used (Adams et al., 2010).  
Based on the study by Keramida et al. (2015) in relation to SUV in 18F-FDG 
PET/CT, all three body size measurements has its own advantage and disadvantages. 
SUVbw commonly concentrates less 18F-FDG than lean tissue but is easily calculated. 
SUVbsa calculation on the other hand are not gender specific and in relation to body 
mass, is found to be lower in larger patients. It also correlates negatively with body 
weight. SUVlbm has the possibility of underestimating the SUV and there is no standard 
formula in measuring lean body mass. 
There are two methods in calculating SUV based on body weight, SUVmean and 
SUVmaximum, which is commonly used. SUVmean integrates the information from 
multiple voxels causing it to be varied based on the voxels included in the average. Hence, 
it is ROI dependent and subjected to both inter- and intraobserver variability. Unlike 
SUVmean, SUVmax measures the value in the highest voxel within an ROI making it to 
be independent of the ROI size, is more reproducible and has less observer variability. 
SUVmax however is more susceptible to image noise compared to SUVmean. In 
addition, there is also SUVpeak which incorporates the average SUV values in a group 
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of voxels around the voxel with highest activity. The idea is to maintain the SUV’s 
reproducibility and to reduce image noise. However, SUVpeak is not widely used in 
clinical practice (Adams et al., 2010). 
 
2.11 QUANTITATIVE BONE SCAN WITH SPECT SUV 
 
 Compared to SPECT, PET system has the capability in generating cross sectional 
images in the unit of kBq/ml. Moreover, dual photon coincidence detection and photon 
attenuation correction in PET allows quantitative assessment. On the contrary, SPECT 
system detects single photon and in general, is not susceptible to photon attenuation 
correction. However, the introduction of hybrid SPECT/CT imaging coupled with 
technological advancement has enabled quantitative assessment in SPECT especially 
SUV calculation due to the improvement in detector performance, development in image 
reconstruction algorithms and the presence of co-registered CT image which allows 
attenuation and scatter correction (Bailey, 2014). 
 Quantification in SPECT based radiotracer such as 99mTc-MDP uptake is basically 
a process of calculating the osseous radioactivity concentration expressed in SUV. Two 
studies have been performed utilizing SPECT SUV with SPECT/CT on bone scintigraphy 
involving the normal spine. Both studies involved quantification of radiopharmaceutical 
in the healthy vertebrae. Cachovan et al. (2013) measures the SPECT SUV of the healthy 
lumbar spine in a population of 50 female patients whereas Kaneta et al. (2016) measures 
the SUV of normal vertebrae using SPECT/CT in a population  of 21 men and 8 women 
with cancer or joint disorders. Both studies advocate further studies in clinical application 
of SPECT SUV. Compared to SUVlbm and SUVbsa, SUVmax has been shown to have 
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the lowest variability in SPECT SUV (Kaneta et al., 2016). In SPECT/CT, there is no 
standard cut off SUV value to differentiate an uptake on bone scan as benign or malignant. 
Hence, SUV measurement has the potential of being a diagnostic tool. The clinical 
utilization of SUVmax has been reported in both 18F-NaF PET/CT and 99mTc-MDP 
SPECT/CT by Muzahir et al.(2015) and Kuji et al.(2017) respectively. 
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3.0 OBJECTIVES OF THE STUDY 
 
3.1 GENERAL OBJECTIVE 
To compare between degenerative joint disease and bone metastases lesions semi-
quantitatively using SPECT SUV. 
 
3.2 SPECIFIC OBJECTIVES 
3.2.1 To determine the SUVmax value in normal vertebra, degenerative joint disease and 
bone metastases. 
3.2.2 To determine the difference in SUVmax value between degenerative joint disease 
and bone metastases. 
3.2.3 To determine the sensitivity and specificity of SUVmax in differentiating 
degenerative joint disease and bone metastases  
 
3.3 RESEARCH HYPOTHESIS 
3.3.1 Null hypothesis: There is no significant difference in SUVmax between 
degenerative joint disease and bone metastases. 
3.3.2 Alternative hypothesis: There is a significant difference in SUVmax between 
degenerative joint disease and bone metastases. 
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